Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples